VERAXA Biotech AG (NASDAQ: VRXA) provided a corporate and pipeline update on Thursday, highlighting progress during the first half of 2026, including continued advancement of its proprietary BiTAC(R) platform and growing interest from potential pharmaceutical partners. The company said its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs and two non-BiTAC assets available for partnering. VERAXA said it plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028.
Company executives also cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company’s differentiated BiTAC platform and its potential to secure strategic collaborations. VERAXA said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies. The full press release is available at https://ibn.fm/xTF5q.
VERAXA Biotech AG, founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), builds next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. The company’s BiTAC(R) platform is a registered trademark of VERAXA Biotech GmbH. For more information, visit the company’s newsroom at http://ibn.fm/VRXA.
The update underscores VERAXA’s strategy to leverage its proprietary platform to address solid tumors while generating near-term value through partnerships. The planned IND/CTA filing for VXA-102 by early 2028 represents a key milestone, potentially positioning VERAXA among the few biotech firms with a clinical-stage T-cell engager targeting solid tumors. The company’s ability to attract pharmaceutical interest at major industry events suggests its BiTAC platform may offer a differentiated approach in the competitive bispecific antibody space. As VERAXA balances internal development with monetizing non-core assets, the coming years will be critical for executing its pipeline and partnership goals.
